Cost-effectiveness analysis of vebreltinib versus gumarontinib in first-line treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation

XIE Yongping, XIE Guofeng, BU Can, CHENG Fang

Chinese Journal of Hospital Pharmacy ›› 2026, Vol. 46 ›› Issue (8) : 930-936.

PDF(1201 KB)
PDF(1201 KB)
Chinese Journal of Hospital Pharmacy ›› 2026, Vol. 46 ›› Issue (8) : 930-936. DOI: 10.13286/j.1001-5213.2026.08.11
Drug and Clinical Practice

Cost-effectiveness analysis of vebreltinib versus gumarontinib in first-line treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 46(8): 930-936 https://doi.org/10.13286/j.1001-5213.2026.08.11

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1201 KB)

Accesses

Citation

Detail
Sections
Recommended
Information
Governed by: China Association for Science and Technology
Sponsored by: Chinese Pharmaceutical Association
Published by: Editorial Office of Chinese Journal of Hospital Pharmacy
ISSN 1001-5213
CN 42-1204/R
Contact
Website Copyright © Chinese Journal of Hospital Pharmacy, All Rights Reserved.
Tel: 027-82836596
E-mail：pharmacy@vip.163.com
Wechat

/

〈 〉